If Israel proceeds with a ground invasion of Gaza (after 2023-10-20), then during the subsequent period of that invasion there will be protests/riots and major social‑media eruptions across the Middle East and globally on an almost daily basis.
“I would consider the riots that we just saw in regards to the hospital and the eruption on social media, to be a prelude or dress rehearsal of what we can expect to happen almost every day if Israel proceeds with the ground invasion of Gaza.”
View on YouTube
Explanation
Israel's ground invasion of Gaza was followed by sustained, near-daily protests and social media activity globally throughout the ensuing conflict.
Following the implementation of the EU Digital Services Act (DSA), large tech platforms may choose to standardize their content-moderation and compliance model globally by applying DSA-style rules in the United States as well, rather than maintaining a separate, more speech-permissive regime in the US.
“What could happen is that because it's easier for companies just to have one approach where they can, there is a risk that these same policies get applied in the US. That is what happened with privacy. Remember, Europe went first with GDPR and then.”
View on YouTube
Explanation
Some 'Brussels effect' spillover of EU content rules into US platform practices occurred, but the US did not adopt DSA-style regulation as formal law.
In response to the EU Digital Services Act, major tech and social media companies (e.g., Google, Meta, etc.) will choose to comply fully with EU content and data-access demands, rapidly implementing EU takedown and transparency requests rather than resisting or exiting the EU market.
“I think the most likely outcome is that tech companies will be craven and they'll fold, and they'll just do whatever these EU commissioners want.”
View on YouTube
Explanation
Major tech platforms have largely complied with EU DSA takedown and transparency requirements rather than exiting the EU market.
Following the implementation of the EU’s new content moderation/censorship regime, major tech and social media companies will comply fully with EU commissioners’ takedown demands and policy requirements rather than resisting them, effectively doing whatever the EU commissioners want.
“I think the most likely outcome is that tech companies will be craven and they'll fold, and they'll just do whatever these EU commissioners want.”
View on YouTube
Explanation
Major tech platforms have largely complied with EU DSA-driven content moderation demands rather than resisting them.
Future GLP-1-based triple agonist drugs (e.g., Mounjaro and similar) will prove more effective at weight loss/metabolic improvement than the current generation of double-agonist GLP-1 drugs.
“My key takeaway is that for many people, from a health perspective, I think that it it could be a really great solution. I think that these triple agonists that are coming out are going to be probably even more effective than these double agonists that we have right now.”
View on YouTube
Explanation
Later triple-agonist drugs (e.g., retatrutide) showed superior weight-loss efficacy in trials compared to earlier double-agonist GLP-1 drugs like Mounjaro/Zepbound.
In retrospect (over the coming years/decades), GLP-1 drugs will be regarded as a major, widely used, disease-modifying ‘wonder drug’ class, comparable in significance and ubiquity to statins in cardiovascular disease.
“I do think that these GLP ones if when we look back on it, we'll probably be like statins.”
View on YouTube
Explanation
GLP-1 drugs have become widely regarded as a transformative, disease-modifying drug class comparable in significance to statins.
Over time, widespread GLP-1 use will likely lead to new public-health issues replacing current obesity problems, for example via physiological adaptation and unchanged or increased caloric intake as users treat the drug as a ‘get out of jail free card.’
“I think the open question for me is if human history is a guide, we're going to replace this issue with a different kind of issue because unfortunately, you know, maybe people take it and then they physiologically adapt, and then they just continue to eat the same or more because they think, wow, this is a get out of jail free card for me.”
View on YouTube
Explanation
There is ongoing discussion of GLP-1 discontinuation and weight regain, but no clear consensus yet that a distinct new public health issue has replaced obesity as predicted.
From late 2023 forward, the extreme outperformance of GLP-1 ‘winner’ stocks versus ‘disrupted’ healthcare stocks is unlikely to persist; the GLP-1 beneficiary basket is overextended and an opposing trade (long disrupted names / short GLP-1 winners) is likely to be favorable as expectations normalize.
“I would, I would, I wouldn't the reason and... The reason is because of two, two, two practical factors. One is that when a, when a market gets this exaggerated, what you're pricing in is essentially like a panacea solution. That and those tend to not really be realistic... so I would just say that it's probably, again, when you see it, an economic trade like this, it's it's it's probably okay to be on the other side of it.”
View on YouTube
Explanation
GLP-1 winner stocks (Lilly, Novo Nordisk) had mixed performance in the following years, with Novo Nordisk notably struggling in 2024-2025, partially matching the predicted normalization but not a clean reversal trade.